Evaluating the potential lifetime health and economic impact of PCV21, an adult-specific 21-valent pneumococcal conjugate vaccine, on invasive pneumococcal disease in adults aged ≥45 years in Spain.
In both age groups, PCV21 showed greater health and economic impact associated with IPD compared with PCV20, underscoring the potential benefits of incorporating PCV21 into adult pneumococcal vaccination strategies in Spain.